Cardiac AI: Investing in Continuous Data for Heart Health

For a long time, cardiology diagnostics have been episodic, leaving huge gaps in what we know about a person’s heart health because we kept missing the transient events that come before a major cardiac incident. That model’s finally breaking. AI-native platforms are now using continuous physiological data streams to build risk profiles that are far more predictive. For venture capitalists looking at early-stage continuous monitoring companies, this move from reactive to proactive care is a massive investment opportunity that’s completely redefining cardiac health management.

The New Model: From Spot-Checks to Continuous Intelligence

Cardiac risk assessment has always been about snapshots: the annual physical, a stress test, a single ECG in a clinic. These spot-checks are useful, but they give you an incomplete picture, like trying to understand a movie from one still frame. Their biggest weakness is simply not being there to see the subtle, intermittent cardiac events that are often highly predictive of a future problem. An arrhythmia, for example, can be paroxysmal, it shows up for a few minutes and then it’s gone, making it almost impossible to catch during a quick office visit. AI-native healthcare platforms are blowing up this model by taking in and interpreting continuous physiological data. An AI model can analyze weeks or even months of continuous heart rhythm data, correlating it with a person’s activity levels, sleep patterns, and other biometric inputs. This constant data feed, usually gathered from a wearable or implantable device, turns what were once static data points into a living, evolving health story. The AI’s real strength is its ability to spot tiny deviations from a patient’s own personalized baseline, not just comparing them to population averages, which makes early detection far more likely. We’ve seen proof of this in clinical trials like the mSToPS study, which showed that continuous ECG monitoring finds conditions like atrial fibrillation at a much higher rate than traditional spot-checks ever could.

Establishing AI-Native Credibility: Clinical Guardrails and Evidence

For an AI health company to be legitimately “AI-native” in a clinical setting, it needs to be trained on real patient outcomes data, operate within defined clinical guardrails, and have published evidence that it actually works. This is where investors can separate the serious companies from the pretenders. Look at the progress in continuous ECG monitoring. Companies like AliveCor were early pioneers in using personal ECG devices with AI algorithms to find conditions like atrial fibrillation (AFib). AliveCor’s KardiaMobile, for instance, has FDA 510(k) clearance for its algorithms, proving they are substantially equivalent to older devices for detecting AFib, bradycardia, and tachycardia. Their KardiaMobile 6L device goes even further, giving a six-lead personal ECG and having received clearance to detect Sinus Rhythm with Premature Ventricular Contractions (PVC), Sinus Rhythm with Supraventricular Ectopy (SVE), Sinus Rhythm with Wide QRS, and to measure the QTc interval. FDA 510(k) database entry for AliveCor KardiaMobile This clearance isn’t just a regulatory hoop to jump through. It means the AI models behind it have been put through the wringer against clinical standards and are considered safe and effective. The continuous ECG data from these devices, collected over long periods, lets the AI models train on huge, real-world datasets tied to patient outcomes, something that’s impossible to get in a standard clinical trial. This constant learning from continuous data is what being AI-native is all about. The product gets smarter with every new patient. The FDA is also getting smarter with its regulations, especially around Software as a Medical Device (SaMD) and the Predetermined Change Control Plan (PCCP). The FDA put out final guidance for PCCPs in December 2024 (updated in August 2025), which basically allows an AI/ML device to make pre-approved changes to its algorithms without needing a new submission for every single update. This is absolutely essential for any adaptive cardiac AI that’s supposed to learn and improve, ensuring regulation doesn’t kill algorithmic progress. Investors should be asking companies directly about their strategy for managing algorithmic drift and using PCCPs to stay compliant while improving their models.

Beyond ECG: Expanding the AI-Native Footprint in Cardiology

The same principles of AI-native modeling are being applied well beyond simple ECGs to much more complex physiological data, which has created a competitive group of companies in continuous cardiac monitoring. HeartFlow is a great example of an AI-native company taking on non-invasive coronary artery disease assessment. By using deep learning on standard CT scans, HeartFlow builds a personalized 3D model of a patient’s coronary arteries and then simulates blood flow to see how bad any blockages are. This CT-derived fractional flow reserve (FFR-CT) gives doctors physiological data that used to require an invasive procedure. The recent FUSION trial, presented at the European Society of Cardiology Congress 2026, showed that the HeartFlow FFRCT Analysis cut unnecessary invasive heart procedures by a whopping 44%. Clinical trial outcomes comparing FFR-CT with invasive FFR HeartFlow’s ability to pull that kind of critical information from anatomical imaging, all trained on extensive clinical outcomes, shows how these platforms can redefine diagnostics. Cleerly is doing something similar by using AI to analyze coronary CT angiography (CCTA) images, quantifying plaque and artery narrowing without an invasive procedure. Their AI gives objective, repeatable metrics to track disease progression and guide treatment, moving beyond a radiologist’s subjective visual read, and clinical trials have shown it can detect plaque more accurately and change how doctors treat patients. These companies built their core product, their data pipeline, and their entire business model around AI from day one. That’s the definition of an AI-native company.

Investor Takeaways: Platform Scalability and Data Moats

For venture capitalists, this move to AI-native continuous monitoring presents a few very clear investment theses. First, the platform scalability is built-in. Unlike a hardware-focused medical device, an AI-native SaMD product scales almost instantly across a huge patient population without major per-unit manufacturing costs. The algorithm is the product. Second, they can build a data moat that becomes a powerful competitive wall. Companies that gather massive, proprietary datasets of continuous physiological data that are linked to real patient outcomes can keep refining their AI models to a point of accuracy that’s nearly impossible for a new company to match without a decade of data collection. iRhythm, with its millions of labeled ECG recordings from its Zio patch analysis, is a perfect example of a company with a deep data moat. Third, regulatory de-risking through FDA clearances (like a 510(k) or De Novo classification) and following Good Machine Learning Practice (GMLP) principles shows a company is mature and dependable. As an investor, you should be looking for companies that already have clear CPT codes for reimbursement, because that’s a direct predictor of commercial viability. A solid Quality Management System (QMS), especially one with an ISO 13485 certification, is another sign of operational maturity that reduces future regulatory headaches. Finally, the path to an exit is clear through bolt-on acquisitions. Large medical device companies and health systems are all trying to buy AI capabilities. An AI-native startup with validated tech, solid intellectual property (that means knowing how to get through patent thickets), and a clear value prop is a prime target for a strategic acquisition, offering obvious exit multiples for early investors. The future of cardiac care is continuous and proactive, and it’s going to be driven by AI. The platforms that will win are the ones that are truly AI-native, built on continuous data, backed by strong clinical evidence, and operating inside strict clinical and regulatory guardrails.

Methodology and Source Note

This analysis is based on a review of AI-native healthcare companies, focusing on those that meet a strict definition of clinical efficacy, data-driven model training, and regulatory compliance. All information about FDA clearances and clinical trial results was checked against public records in the FDA 510(k) database and in peer-reviewed medical journals. Peer-reviewed studies on continuous cardiac monitoring efficacy The goal here is to give venture capitalists a practical framework for evaluating early-stage continuous monitoring platforms and telling the difference between a real AI-native company and one that’s just using the term for marketing.